Results 201 to 210 of about 34,373 (228)

Polychlorinated biphenyls (PCBs) interact with drug metabolism in vivo. [PDF]

Arch Toxicol
Müller JP, Rengelshausen J, Laieb S, Safavi M, Kaifie A, Esser A, Schettgen T, Bertram J, Krabbe J, Schaeffeler E, Sarömba J, Just KS, Tremmel R, Schwab M, Stingl JC, Kraus T, Ziegler P.   +16 more
europepmc   +1 more source

SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients. [PDF]

PLoS One
Murtola TJ, Skantsi KM, Siltari A, Talala K, Taari K, Tammela TLJ, Schleutker J, Auvinen A, Sipeky C.   +8 more
europepmc   +1 more source

The Evolution and Future Directions of PBPK Modeling in FDA Regulatory Review. [PDF]

Pharmaceutics
Li Y, Sun H, Zhang Z.
europepmc   +1 more source

Analysis of CYP2C9 promotor variations and possible links to the CYP2C9 2 and CYP2C9 3 exon variants.

, 2018
Schubert, C., Cubic, I., Kirchheiner, Julia, Brockmoeller, Juergen, Roots, Ivar   +4 more
openaire   +1 more source

Empirical Drug Dosage Validates Pharmacogenomic Associations in All of Us. [PDF]

Clin Transl Sci
Matthias J, Falaguera MJ, Altman RB.
europepmc   +1 more source

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain. [PDF]

Drug Des Devel Ther
Yao H, Luo X, Yuan J, Zhang H, An H, Feng Y.   +5 more
europepmc   +1 more source

Factors affecting CYP2C9-mediated metabolism

, 2019
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9*2 AND CYP2C9*3) IN LORNOXICAM 5′-HYDROXYLATION

Drug Metabolism and Disposition, 2004
The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5'-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.
Izumi, Iida, Atsunori, Miyata, Masayuki, Arai, Mitsuyo, Hirota, Masayuki, Akimoto, Shohei, Higuchi, Kaoru, Kobayashi, Kan, Chiba   +7 more
openaire   +2 more sources

An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62

Chemico-Biological Interactions, 2020
Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes.
Hao, Chen, Da-Peng, Dai, Shan, Zhou, Jian, Liu, Shuang-Hu, Wang, Hua-Lan, Wu, Quan, Zhou, Pei-Wu, Geng, Jia, Chong, You, Lü, Jian-Ping, Cai, Jie-Fu, Yang   +11 more
openaire   +2 more sources

ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS

Drug Metabolism and Disposition, 2005
CYP2C9 is an important member of the cytochrome P450 enzyme superfamily with some 12 CYP2C9 alleles (*1-*12) being previously reported. Recently, we identified a new CYP2C9 allele with a Leu90Pro mutation in a Chinese poor metabolizer of lornoxicam [Si D, Guo Y, Zhang Y, Yang L, Zhou H, and Zhong D (2004) Pharmacogenetics 14:465-469].
Yingjie, Guo, Yifan, Zhang, Ying, Wang, Xiaoyan, Chen, Dayong, Si, Dafang, Zhong, J Paul, Fawcett, Hui, Zhou   +7 more
openaire   +2 more sources